These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 18989142)
21. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Russmann S; Barguil Y; Cabalion P; Kritsanida M; Duhet D; Lauterburg BH Eur J Gastroenterol Hepatol; 2003 Sep; 15(9):1033-6. PubMed ID: 12923378 [TBL] [Abstract][Full Text] [Related]
22. Suspected black cohosh hepatotoxicity--challenges and pitfalls of causality assessment. Teschke R; Bahre R; Genthner A; Fuchs J; Schmidt-Taenzer W; Wolff A Maturitas; 2009 Aug; 63(4):302-14. PubMed ID: 19586731 [TBL] [Abstract][Full Text] [Related]
26. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Sarris J; LaPorte E; Schweitzer I Aust N Z J Psychiatry; 2011 Jan; 45(1):27-35. PubMed ID: 21073405 [TBL] [Abstract][Full Text] [Related]
27. [Acute hepatitis due to kava-kava and St John's Wort: an immune-mediated mechanism?]. Teschke R Dtsch Med Wochenschr; 2006 Aug; 131(34-35):1880-1; author reply 1882-3. PubMed ID: 16915552 [No Abstract] [Full Text] [Related]
28. Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods. Teschke R; Frenzel C; Schulze J; Eickhoff A World J Gastroenterol; 2013 May; 19(19):2864-82. PubMed ID: 23704820 [TBL] [Abstract][Full Text] [Related]
29. A systematic review of the safety of kava extract in the treatment of anxiety. Stevinson C; Huntley A; Ernst E Drug Saf; 2002; 25(4):251-61. PubMed ID: 11994028 [TBL] [Abstract][Full Text] [Related]
30. Treatment of anxiety, tension and restlessness states with Kava special extract WS 1490 in general practice: a randomized placebo-controlled double-blind multicenter trial. Gastpar M; Klimm HD Phytomedicine; 2003 Nov; 10(8):631-9. PubMed ID: 14692723 [TBL] [Abstract][Full Text] [Related]
31. Kava treatment in patients with anxiety. Geier FP; Konstantinowicz T Phytother Res; 2004 Apr; 18(4):297-300. PubMed ID: 15162364 [TBL] [Abstract][Full Text] [Related]
32. Tradition and toxicity: evidential cultures in the kava safety debate. Baker JD Soc Stud Sci; 2011 Jun; 41(3):361-84. PubMed ID: 21879526 [TBL] [Abstract][Full Text] [Related]
33. Herbal hepatotoxicity and WHO global introspection method. Teschke R; Eickhoff A; Wolff A; Frenzel C; Schulze J Ann Hepatol; 2013; 12(1):11-21. PubMed ID: 23293189 [TBL] [Abstract][Full Text] [Related]
35. Kava Hepatotoxicity: Are we any closer to the truth? Anke J; Ramzan I Planta Med; 2004 Mar; 70(3):193-6. PubMed ID: 15114493 [TBL] [Abstract][Full Text] [Related]
36. Risk of kava hepatotoxicity and the FDA consumer advisory. Teschke R; Schulze J JAMA; 2010 Nov; 304(19):2174-5. PubMed ID: 21081732 [No Abstract] [Full Text] [Related]
37. Kava, the anxiolytic herb: back to basics to prevent liver injury? Teschke R; Sarris J; Glass X; Schulze J Br J Clin Pharmacol; 2011 Mar; 71(3):445-8. PubMed ID: 21284704 [TBL] [Abstract][Full Text] [Related]
38. Initially purported hepatotoxicity by Pelargonium sidoides: the dilemma of pharmacovigilance and proposals for improvement. Teschke R; Frenzel C; Wolff A; Herzog J; Glass X; Schulze J; Eickhoff A Ann Hepatol; 2012; 11(4):500-12. PubMed ID: 22700632 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Malsch U; Kieser M Psychopharmacology (Berl); 2001 Sep; 157(3):277-83. PubMed ID: 11605083 [TBL] [Abstract][Full Text] [Related]